Q-omics provides the consensus-scored SHISA5 profile across patient tissues and cancer cell-line models. SHISA5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SHISA5 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SHISA5 RNA expression shows 18,102 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where SHISA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHISA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHISA5 survival associations across molecular data types. SHISA5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHISA5 RNA expression–survival associations across cancer types. High SHISA5 expression shows unfavorable associations in KIRC, LIHC, LGG, ACC and LUAD, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SHISA5 RNA expression.
This table summarizes SHISA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SHISA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHISA5 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, KIRP, LIHC and THCA. The KIRC box plot shows higher SHISA5 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with SHISA5 in patient tissues and cancer cell lines. In patient samples, SHISA5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHISA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
